Among these, aberrations in BRAF, MEGF6 (EGFL6), DAXX, RAG1, DDX54, and ASPSCR1 genes have been previously linked to neuroblastoma pathogenicity, drug resistance and/or RAS-MAPK activation (refs. 22, 49–55; Table 3). Here, MEGF6 is linked to neuroblastoma.